Publications Le 07 Déc 2020 Publications Filtrer nos publications par : Année20232022202120202019201820172016201520142013201220112010200920082007200620052004200320022001 2011 HMGB-1 promotes fibrinolysis and reduces neurotoxicity mediated by tissue plasminogen activator. Owing to its ability to generate the clot-dissolving protease plasmin, tissue plasminogen activator (tPA) is the only approved drug for (…) Consulter 2011 Tissue plasminogen activator prevents white matter damage following stroke. Tissue plasminogen activator (tPA) is the only available treatment for acute stroke. In addition to its vascular fibrinolytic action, tPA (…) Consulter 2011 Stroke and the immune system: from pathophysiology to new therapeutic strategies. Stroke is the second most common cause of death worldwide and a major cause of acquired disability in adults. Despite (…) Consulter 2011 Enriched housing reverses age-associated impairment of cognitive functions and tPA-dependent maturation of BDNF. Although tissue type plasminogen activator (tPA) and brain derived neurotrophic factor (BDNF) have been extensively described to influence brain outcomes (…) Consulter 2010 Functional occurrence of the interaction of tissue plasminogen activator with the NR1 Subunit of N-methyl-D-aspartate receptors during stroke. Despite its fibrinolytic effect, tissue-type plasminogen activator (tPA) displays deleterious effects in the brain, including proexcitotoxicity, that can reduce the (…) Consulter 2011 Interaction study between rtPA and bevacizumab. Consulter Pages: First Page123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960616263646566676869707172737475767778798081828384Last PageLoad More Retour
